Eluxadoline Production Cost Reports

The report provides a detailed analysis essential for establishing an eluxadoline production plant. It encompasses all critical aspects necessary for eluxadoline production, including the cost of eluxadoline production, eluxadoline plant cost, eluxadoline production costs, and the overall eluxadoline production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an eluxadoline production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Eluxadoline is a pharmaceutical compound mainly used for the treatment of diarrhoea-predominant irritable bowel syndrome in adults. It is widely used as a prescription medicine for the treatment of adults suffering from irritable bowel syndrome with diarrhoea (IBS-D). It works by acting on specific receptors in the gut to reduce bowel spasms, control diarrhoea, and relieve abdominal pain.

It helps manage this condition by working on certain receptors in the gut to reduce bowel contractions and control symptoms like abdominal pain and frequent loose stools. The drug is taken orally and is used under medical guidance, especially for long-term symptom control. It is especially useful for patients who have not responded well to traditional antidiarrheal drugs. It serves an important role in improving daily comfort and quality of life for patients dealing with chronic gastrointestinal conditions. It is also used as a reference drug in ongoing studies to support the development of targeted therapies for digestive health.

The primary factor that drives the market for eluxadoline is its demand as a prescription medicine used in the pharmaceutical and healthcare industry for the management of digestive disorders. Its application as an antidiarrheal drug for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults significantly promotes its demand in the pharmaceutical industry. Its demand as a gastrointestinal drug for long-term symptom relief in IBS-D patients and in the treatment of other functional bowel disorders also supports its market expansion. Its role in reducing abdominal pain, bowel urgency, and frequent diarrhoea makes it a widely used option for long-term symptom control in adult patients.

Rising prevalence of digestive disorders, increasing diagnosis rates, and growing awareness about targeted gastrointestinal therapies significantly support its demand. Moreover, production efficiency, reliable supplier networks, and effective distribution systems play an important role in shaping its procurement trends globally. Various factors, including the cost and availability of active pharmaceutical ingredients, regulatory approvals, quality standards, and compliance with safety guidelines, influence industrial eluxadoline procurement.

Raw Material for Eluxadoline Production

According to the eluxadoline production plant project report, the major raw materials for eluxadoline production include N-Boc-protected aminoester, N-Cbz-L-alanine, 2-Aminoacetophenone hydrochloride, and Aryl Aldehyde.

Production Process of Eluxadoline

The extensive eluxadoline production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of eEluxadoline begins with preparing a main intermediate from an N-Boc-protected aminoester through a series of four steps. A triflate is first formed and then converted into an aryl acid using a carbonylation reaction. This acid is amidated to form an amide and then undergoes ester hydrolysis to give the coupling component. Separately, N-Cbz-L-alanine is coupled with 2-aminoacetophenone to form an intermediate that is cyclized into an imidazole, which is then deprotected to release a free amine. This amine undergoes reductive amination with an aryl aldehyde, followed by coupling with N-Boc-protected 2,6-dimethyl-L-tyrosine amide derivative to build the core structure of Eluxadoline. The final steps involve ester hydrolysis and Boc deprotection to produce Eluxadoline as the desired product.

Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and delta-opioid receptor antagonist that appears as a white or off-white solid powder. The molecular formula of the compound is C32H35N5O5, and its molecular mass is 569.66 g/mol. It shows limited solubility in water due to its zwitterionic nature, which results in a negatively charged molecule across the gastrointestinal pH range. It is slightly soluble in dimethyl sulfoxide and methanol. The compound is formulated as tablets containing 75 mg or 100 mg of eluxadoline for oral administration and should be taken with food. The melting point of the compound is >180 degree Celsius, and its boiling point is around 834.2 degree Celsius. The compound has a terminal plasma half-life of approximately 3.7 to 6 hours and is primarily eliminated through faecal excretion. It is recommended to use the lower dose of 75 mg twice daily in patients with mild or moderate hepatic impairment.